Navigation Links
Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
Date:3/24/2009

ANTONY, France, March 24 /PRNewswire-FirstCall/ -- Stallergenes S.A. and Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary of Solvay Group) announce the signing of an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment products in Russia and the Commonwealth of Independent States (CIS).

With an estimated 20 million allergy sufferers and a strong demand on the part of the medical community for quality products, the Russian market represents a real opportunity for Stallergenes.

The main products in Stallergenes' injectable and sublingual ranges will soon be the subject of registration applications. This partnership will enable Stallergenes to meet more than 80% of the needs of allergy sufferers in Russia and the CIS by 2011.

"We're delighted to be teaming up with Solvay Pharmaceuticals to target the potential growth this new market represents. Thanks to its franchise and its considerable expertise recognized by allergy specialists, Solvay Pharmaceuticals will enable us to promote the desensitization standardized products, and notably the sublingual route, and their benefits for patients," declared Albert Saporta, Stallergenes' Chairman and CEO.

"We're tremendously enthusiastic about the prospect of collaborating with the world leader in sublingual desensitization therapy and making its innovative standardized products available to practitioners," emphasizes Mr. Jens Neuschaefer, Vice President, Regional Director, Solvay Pharmaceuticals.

*countries concerned: Russia, Georgia, CIS (Commonwealth of Independent States: Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldavia, Uzbekistan, Russia, Tajikistan, Turkmenistan, and Ukraine).

About Stallergenes' International Development

Today, Stallergenes markets its products in more than 50 different countries, via 11 subsidiar
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
2. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
3. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
4. Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
5. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
6. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
7. Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany
8. STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure
9. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
10. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
11. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014 /PRNewswire/ ... announced today that Medtronic, Inc. (NYSE: ... to the U.S. Food and Drug Administration (FDA) ... II implantable drug infusion system (including a newly ... ® (treprostinil) Injection delivered intravenously to patients ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... 23, 2014 Earlier this year in ... Sherley, director of the Adult Stem Cell Technology Center, ... overlooked and under appreciated unique property of adult tissue ... Stem Cells: Misunderstood in the Past, Important for the ... participants. He gave the address at the 4th ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Positive results from Pyratine XR(TM) rosacea-specific study also slated ... March 8, 2009 - NAPA, Calif., March 5 ... sciences company engaged in the development of technologies that ... Pyratine XR(TM) is officially launching at the American Academy ...
... the launch of a suite of miRNA functional ... vector based precursor miRNA expression clones; 2) miTarget(TM) ... 3) All-in-One(TM) miRNA RT-qPCR system.Constructed in a lentiviral ... collections cover all known miRNAs for human ...
... 5 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology therapies, today announced that it will hold ... quarter and year-end financial results and provide a ... the Company,s lead product candidate.Jerry McMahon, Ph.D., chairman ...
Cached Biology Technology:Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 3GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools 2Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12 2
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... International Liver CongressTM 2013 has demonstrated the, accuracy of ... Non Alcoholic Fatty Liver disease (NAFLD) comprises two ... relatively benign and one group with NASH which may ... the only means of distinguishing the two was to ...
... 23, 2013  Aware, Inc. (NASDAQ: AWRE ), a ... assurance software products, today reported financial results for its first ... the first quarter of 2013 was $5.6 million, an increase ... last year. Operating income before patent related income in the ...
... April 23, 2013 Governor Tom Corbett ... with its 2013 BIO Governor of the Year Award in ... and public health sectors within Pennsylvania . ... BIO International Convention in Chicago, Ill. ...
Cached Biology News:Aware, Inc. Reports First Quarter 2013 Financial Results 2Aware, Inc. Reports First Quarter 2013 Financial Results 3Aware, Inc. Reports First Quarter 2013 Financial Results 4Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award 2Governor Corbett Presented 2013 Biotechnology Industry Organization Governor of the Year Award 3
Fluorescein-CSCSSLMDKECVYFCHLDIIW (Disulfide bridge: 1-15 and 3-11)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
VMAT 2 (N-19)...
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: